Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 7/20 | 0.57 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | IDH1 | O75874 | 2/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6334745 | 1.00 | NAAA (0.57) | NAAAFKBP1ANPC1TDP1FAAH | |
| SCHEMBL345276 | 1.00 | NAAA (0.57) | NAAAFKBP1ANPC1TDP1FAAH | |
| SCHEMBL2872894 | 0.94 | NAAA (0.52) | NAAAFKBP1ANPC1TDP1FAAH | |
| SCHEMBL2872897 | 0.94 | NAAA (0.52) | NAAAFKBP1ANPC1TDP1FAAH | |
| SCHEMBL6788947 | 0.93 | NAAA (0.51) | NAAAFKBP1ANPC1TDP1FAAH | |
| SCHEMBL4521529 | 0.93 | NAAA (0.51) | NAAAFKBP1ANPC1TDP1FAAH | |
| SCHEMBL22800346 | 0.93 | NAAA (0.51) | NAAAFKBP1ANPC1TDP1FAAH | |
| SCHEMBL22800345 | 0.93 | NAAA (0.51) | NAAAFKBP1ANPC1TDP1FAAH | |
| SCHEMBL16594224 | 0.93 | NAAA (0.60) | NAAAFKBP1ANPC1TDP1FAAH | |
| SCHEMBL16594226 | 0.93 | NAAA (0.60) | NAAAFKBP1ANPC1TDP1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605451-B2 | Targeted plasma protein degradation | NOVARTIS AG (CH) | 2026-04-21 | — | — | US | disclosed |
| CN-113166114-B | Cyclic tetramer compounds as inhibitors of proprotein convertase subtilisin/KEXIN type 9 (PCSK 9) for the treatment of metabolic disorders | 诺华股份有限公司 | 2025-01-03 | — | — | CN | disclosed |
| US-20230398224-A1 | TARGETED PLASMA PROTEIN DEGRADATION | NOVARTIS AG (CH) | 2023-12-14 | — | — | US | disclosed |
| US-20230398224-A1 | TARGETED PLASMA PROTEIN DEGRADATION | NOVARTIS AG (CH) | 2023-12-14 | — | — | US | disclosed |
| US-20230398224-A1 | TARGETED PLASMA PROTEIN DEGRADATION | NOVARTIS AG (CH) | 2023-12-14 | — | — | US | disclosed |
| US-20230364272-A1 | THERANOSTIC COMPOUNDS | UNIVERSITY OF CAPE TOWN (ZA) | 2023-11-16 | — | — | US | disclosed |
| US-20230364272-A1 | THERANOSTIC COMPOUNDS | UNIVERSITY OF CAPE TOWN (ZA) | 2023-11-16 | — | — | US | disclosed |
| US-11813306-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | NOVARTIS AG (CH) | 2023-11-14 | — | — | US | disclosed |
| US-11813306-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | NOVARTIS AG (CH) | 2023-11-14 | — | — | US | disclosed |
| US-11813306-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | NOVARTIS AG (CH) | 2023-11-14 | — | — | US | disclosed |
| WO-2006099352-A1 | NOVEL ISOPHTHALATES AS BETA-SECRETASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-21 | — | — | WO | disclosed |
| US-20060040999-A1 | CETP inhibitors | MERCK SHARP & DOHME LLC | 2006-02-23 | — | — | US | disclosed |
| WO-2006014413-A1 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| EP-0912545-A1 | HYDROXAMIC ACID BASED COLLAGENASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 1999-05-06 | — | — | EP | disclosed |
| WO-1997026257-A1 | HYDROXAMIC ACID BASED COLLAGENASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 1997-07-24 | — | — | WO | disclosed |
| EP-0383635-B1 | Peptides having renin inhibitory activity their preparation and use | SANKYO CO (JP) | 1995-07-12 | — | — | EP | disclosed |
| US-5378689-A | Hypotensive agents; administrable by mouth | SANKYO COMPANY, LIMITED (JP) | 1995-01-03 | — | — | US | disclosed |
| EP-0480714-A2 | HIV protease inhibitors having symmetrical structure | MERCK & CO. INC. (US) | 1992-04-15 | — | — | EP | disclosed |
| EP-0383635-A2 | Peptides having renin inhibitory activity their preparation and use | Sankyo Company Limited (JP) | 1990-08-22 | — | — | EP | disclosed |
| EP-0228192-A2 | Renin-inhibitory oligopeptides, their preparation and use | SANKYO COMPANY LIMITED (JP) | 1987-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040999-A1 | CETP inhibitors | CETP, APOB, MTTP | NAAA 1402/4885FKBP1A 3130/4885NPC1 8/4885 |
| US-11813306-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | PCSK9, PCSK7, PCSK6 | NAAA 1406/4885FKBP1A 1797/4885NPC1 12/4885 |
| US-20230364272-A1 | THERANOSTIC COMPOUNDS | MMP12, TIMP3, CTSZ | NAAA 79/4885FKBP1A 2085/4885NPC1 545/4885 |
| US-12605451-B2 | Targeted plasma protein degradation | M6PR, ASGR1, IGF2R | NAAA 2038/4885FKBP1A 1905/4885NPC1 542/4885 |
| US-20230398224-A1 | TARGETED PLASMA PROTEIN DEGRADATION | M6PR, ASGR1, IGF2R | NAAA 2233/4885FKBP1A 2558/4885NPC1 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.